FDA says nada to Lemtrada; will Sanofi be willing to invest in additional trials?

Eric Palmer

intends to appeal the FDA's denial of , its multiple sclerosis drug that was a key reason it paid $ 20.1 billion to buy Genzyme two years ago. But will the company more money in the drug, given that after three more years of it will be far behind competitors?

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS